NCT04135898已完成1 期
A Randomized, Double-blind, Phase I Study Comparing the Pharmacokinetic and Safety of SIBP-04 and Bevacizumab in Healthy Male Subjects
Shanghai Institute Of Biological Products1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2019年10月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- AUC0-t
研究概览
简要总结
This is a randomised, double-blind, positive drug parallel controlled clinical trial in China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subjects who are able and willing to give written informed consent.
- •18-45 years old, male.
- •Body mass index (BMI): 18-26 kg/m2 (including 18 kg/m2 and 26 kg/m2), and weighing between 50-80 kg (including 50 kg and 80 kg).
- •Subjects determined healthy by Vital signs, physical examination, laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, fecal occult blood, etc.), 12-lead electrocardiogram, chest X-ray, abdominal ultrasound, urinary ultrasound, without any clinically significant abnormality judged by the investigator.
- •Subjects who are willing to comply with the contraception restrictions from signing of the informed consent form until 6 months after the infusion of the test drug.
- •Subjects who can participate in the visit on time and complete the visit.
排除标准
- •Subjects with the following diseases, including but not limited to: nervous system, cardiovascular system, blood and lymphatic system, immune system, digestive system, respiratory system, metabolism and bone diseases.
- •History of digestive tract perforation or digestive tract disease.
- •Subjects who are allergic to Avastin® and its ingredients.
- •History of autoimmune diseases or allergic diseases.
- •History of clinically significant proteinuria (urine routine examination, urinary protein 2+and above) or proteinuria judged by the investigator.
- •Any inherited predisposition to bleeding or to thrombosis or history of non traumatic hemorrhage (i.e., requiring medical intervention), thromboembolic event or any condition which may increase bleeding risk including clotting disorders, thrombocytopenia (platelet count < 125000/µL) or an international normalized ratio (INR) higher than 1.
- •Subjects who did strenuous exercise 96 hours before the test, or participate in intense physical activity within 30 days after the scheduled dose, including physical contact or impact sports;
- •Subject with a family history of cancer or a malignant tumor within the past 5 years.
- •Abnormal ECG with clinical significance judged by the Investigator.
- •Subjects with relevant family history of hypertension or abnormal blood pressure at screening or admission to the study center (Day 1): (Systolic blood pressure ≤ 90mmHg or ≥ 140mmHg, or / and diastolic blood pressure ≤ 60mmHg or ≥ 90mmHg), heart rate ≤ 50bpm or ≥ 100bpm.
- •Subjects who have acute or chronic infectious diseases and have clinical significance during the screening and admission studies, or hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), hepatitis B surface antigen (HBsAg), syphilis test positive during the screening.
- •History of prior exposure to bevacizumab or any anti VEGF monoclonal antibodies or proteins.
- •Live virus vaccination within 3 months prior to study drug administration， or prior exposure to any other investigational monoclonal antibody within 9 months.
- •Intake of prescribed or over the counter drugs within 5 half-life of the drug or 2 weeks prior to the use of the test drug, or intake of herbal drugs or dietary supplements within 28 days prior to randomization.
- •Use of any investigational drug in any clinical study within the 3 months prior to Sign informed consent.
- •Blood loss or blood donation (including blood components donation) ≥ 400 mL or blood transfusion within 3 months before study drug administration.
- •Unhealed wound ulcers or fractures, or major surgery within 2 months prior to randomization or expected major surgery during the study period or 2 months after the end of the study.
- •Plan to receive oral or dental surgery during the study period.
- •History of alcohol abuse or a positive alcohol breath test before study drug administration.
- •History of drug abuse, or have positive drug screening results.
- •Subjects who have more than 5 cigarettes per day within 3 months before enrollment.
- •Others that are not in compliance with the enrollment judged by the investigator.
研究组 & 干预措施
SIBP-04
Experimental
干预措施: SIBP-04 (Drug)
Bevacizumab
Active Comparator
干预措施: Bevacizumab (Drug)
结局指标
主要结局
AUC0-t
时间窗: From 0 to day 71
Area under the concentration time curve of the analyte in serum over the time interval from 0 to the last measurable concentration at time "t"
次要结局
- Tmax(From 0 to day 71)
- CL(From 0 to day 71)
- Cmax(From 0 to day 71)
- AUCinf(From 0 to day 71)
- t1/2(From 0 to day 71)
- Immunogenicity(From 0 to day 71)
- λz(From 0 to day 71)
- Vd(From 0 to day 71)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
PK and Safety of SCT510HealthyNCT05113511First Affiliated Hospital of Zhejiang University84
已完成
1 期
The Safety, Tolerability and Pharmacokinetic Study of RAY1225ObeseHealthyNCT05835752Guangdong Raynovent Biotech Co., Ltd68
已完成
1 期
MSB11022 in Healthy SubjectsHealthy SubjectsNCT03014947Fresenius Kabi SwissBioSim GmbH237
进行中（未招募）
1 期
Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy SubjectsHealthyNCT05125211Zhejiang Echon Biopharm Limited91
进行中（未招募）
1 期
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT06175338Mabscale, LLC208